A preclinical signal: studying Borrelia motility under nonthermal electromagnetic-field exposure
Citation: Erik A. Nilsen, Heather Adkison, John R. Martinez, Nevena Zubcevik, and Monica E. Embers. Arresting spirochetes: nonthermal extremely low-frequency electromagnetic field exposure suppresses Borrelia burgdorferi motility in vitro. Frontiers in Medicine, 2026. DOI: 10.3389/fmed.2026.1886935
Division of Immunology at the Tulane National Biomedical Research Center, Tulane University
Published in Frontiers in Medicine on August 11, 2026, this preclinical in-vitro study examined whether a defined nonthermal extremely low-frequency electromagnetic field exposure produced a measurable change in Borrelia burgdorferi motility in laboratory culture.
Research stage: preclinical and in vitro. This paper does not establish a Lyme disease treatment, cure, clinical efficacy, or use in people.
The research question
The study asked a bounded laboratory question: under controlled in-vitro conditions, could a nonthermal extremely low-frequency electromagnetic field exposure produce a reproducible change in the motility of Borrelia burgdorferi?
What the investigators reported
The investigators reported suppression of Borrelia burgdorferi motility in vitro. A platform-selected candidate produced a measurable, replicated result on the first experimental day. Peer-reviewed publication followed approximately six months after the initial laboratory work.
Why this is a Discovery R&D proof point
For Electrome, the milestone is evidence that an AI-guided research workflow can connect a defined biological question, evidence review, hypothesis ranking, signal modeling, protocol design, hardware-controlled laboratory experimentation, statistical analysis, human scientific review, and publication. It is not evidence of a clinical product.
Human scientific review
Models and specialized research agents can organize evidence, compare hypotheses, and support mathematical and statistical work. Scientists determine the question, review assumptions, operate the experiments, interpret results, decide whether replication is adequate, and determine what can responsibly move forward.
Authors and affiliation
Erik A. Nilsen, Heather Adkison, John R. Martinez, Nevena Zubcevik, and Monica E. Embers. Dr. Embers's current affiliation is the Division of Immunology at the Tulane National Biomedical Research Center, Tulane University.
Interpretation boundary
The findings are limited to the reported laboratory model and exposure conditions. They do not demonstrate safety or efficacy in people, do not change clinical standards of care, and do not support patient-care guidance. No Electrome product is cleared or marketed for Lyme disease or any infectious condition.